Search results
Showing 51 to 100 of 298 results for breast cancer
of 19 Taking a medicine to reduce the chance of developing breast cancer Decision aid for postmenopausal women at moderately increased...
Evidence-based recommendations on abemaciclib (Verzenios) with fulvestrant for hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy in adults.
Evidence-based recommendations on lapatinib (Tyverb) and trastuzumab (Herceptin) for treating metastatic hormone receptor-positive breast cancer that overexpresses HER2 in adults.
In development [GID-TA10919] Expected publication date: TBC
NICE is unable to make a recommendation on olaparib (Lynparza) for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy. This is because AstraZeneca did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA762
In development [GID-TA11263] Expected publication date: TBC
In development [GID-NG10415] Expected publication date: TBC
In development [GID-NG10419] Expected publication date: 31 March 2025
Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (CG104)
This guideline covers diagnosing and managing secondary cancer in people aged 18 and over when the site of the primary cancer is unknown. This includes people who have had treatment for cancer before. It aims to improve quality of life by offering advice on tests for identifying the site of the primary cancer and options for managing the person’s condition.
In development [GID-TA11439] Expected publication date: TBC
In development [GID-DG10075] Expected publication date: TBC
In development [GID-TA11513] Expected publication date: TBC
NICE has developed a medtech innovation briefing (MIB) on AlignRT in breast cancer radiotherapy .
We are listening to your views on this NICE guideline. Comments close 19 April 2024.
Contrast-enhanced spectral mammography for breast cancer (MIB304)
NICE has developed a medtech innovation briefing (MIB) on contrast-enhanced spectral mammography for breast cancer .
MammaTyper in vitro diagnostic test for determining breast cancer subtypes (MIB135)
NICE has developed a medtech innovation briefing (MIB) on the MammaTyper in vitro diagnostic test for determining breast cancer subtypes .
Magseed for locating impalpable breast cancer lesions (MIB236)
NICE has developed a medtech innovation briefing (MIB) on Magseed for locating impalpable breast cancer lesions .
Axxent electronic brachytherapy system for early stage breast cancer (MIB76)
NICE has developed a medtech innovation briefing (MIB) on Axxent electronic brachytherapy system for early stage breast cancer
improvement concerning the referral of patients with breast symptoms (including those suspicious of breast cancer) from...
Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer (MTG72)
Evidence-based recommendations on Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer.
View recommendations for MTG72Show all sections
L-Dex U400 for lymphoedema after breast cancer treatment (MIB111)
NICE has developed a medtech innovation briefing (MIB) on L-Dex U400 for lymphoedema after breast cancer treatment .
Breast reconstruction using lipomodelling after breast cancer treatment (IPG417)
Evidence-based recommendations on breast reconstruction using lipomodelling after breast cancer treatment. This involves taking fat from the abdomen or thighs and injecting it into the breast in the area of the deformity caused by surgery.
View recommendations for IPG417Show all sections
Sections for IPG417
Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours
Physical activity: brief advice for adults in primary care (PH44)
This guideline covers providing brief advice on physical activity to adults in primary care. It aims to improve health and wellbeing by raising awareness of the importance of physical activity and encouraging people to increase or maintain their activity level.
Endoscopic mastectomy and endoscopic wide local excision for breast cancer (IPG296)
Evidence-based recommendations on endoscopic mastectomy and endoscopic wide local excision for breast cancer. This involves removing part or all of the breast using special instruments inserted through small cuts in the skin (keyhole surgery).
View recommendations for IPG296Show all sections
Sections for IPG296
Breast cancer mortality rates Subject(s): Cancer, Mortality NICE identity code: CCG04
Evidence-based recommendations on interstitial laser therapy for breast cancer. This involves using laser energy to destroying the cancer cells.
View recommendations for IPG89Show all sections
Endoscopic axillary lymph node retrieval for breast cancer (IPG147)
Evidence-based recommendations on endoscopic axillary lymph node retrieval for breast cancer. This involves using narrow instruments to remove the lymph nodes through small, rather than large, openings to reduce the risk of infection and other problems.
View recommendations for IPG147Show all sections
This guideline covers identifying children, young people and adults with symptoms that could be caused by cancer. It outlines appropriate investigations in primary care, and selection of people to refer for a specialist opinion. It aims to help people understand what to expect if they have symptoms that may suggest cancer.
Show all sections
Sections for NG12
Evidence-based recommendations on brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision. This involves inserting radioactive sources into the space in the breast where tissue has been removed to minimise the chances of the cancer coming back.
View recommendations for IPG268Show all sections
Sections for IPG268
Mortality from breast cancer in females Subject(s): Cancer Date of publication: 27 May 2020
having a stroke. Intrabeam radiotherapy for treating early breast cancer Use this decision aid to help you and your healthcare...
for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945] 3 September 2020 TBC Afamelanotide for treating...
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (TA208)
Evidence-based recommendations on trastuzumab (Herceptin) for treating HER2-positive metastatic gastric cancer in adults.
CG164/4 Question Chemoprevention to reduce incidence of breast cancer:- A randomised controlled trial is recommended to compare the...
Recommendation ID NG23/1 Question Women with breast cancer:- What is the safety and effectiveness of alternatives to systemic HRT as...
NG23/2 Question Effects of HRT on breast cancer risk:- What is the difference in the risk of breast cancer in menopausal...
NG101/1 Question Surgery to the breast:- What is the optimum tumour-free margin width after breast-conserving surgery for...
NICE has developed a medtech innovation briefing (MIB) on the ATEC breast biopsy system
NICE has developed a Medtech Innovation Briefing (MIB) on Aixplorer ShearWave Elastography for ultrasound imaging and assessing suspicious breast lesions
Managed access allows patients to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.
side-effects at first, but not every woman does. These include headaches, nausea, breast tenderness and mood changes. If they do not...
NICE has developed a medtech innovation briefing (MIB) on artificial intelligence in mammography .
This quality standard covers diagnosing and managing menopause in women, including women who have premature ovarian insufficiency (menopause before the age of 40, which can occur naturally or as a result of medical or surgical treatment). It describes high-quality care in priority areas for improvement.
View quality statements for QS143Show all sections
Sections for QS143
- Quality statements
- Quality statement 1: Diagnosing perimenopause and menopause
- Quality statement 2: Diagnosing premature ovarian insufficiency
- Quality statement 3: Managing premature ovarian insufficiency
- Quality statement 4: Reviewing treatments for menopausal symptoms
- Quality statement 5: Information for women having treatment likely to cause menopause
- About this quality standard
women over 50 years with a personal history of breast cancer. Studies should include sub-analysis for breast density. [new...
Laparoscopic mobilisation of the greater omentum for breast reconstruction (IPG253)
Evidence-based recommendations on laparoscopic mobilisation of the greater omentum for breast reconstruction. This involves removing the fatty tissue using special instruments through small cuts in the abdomen.
View recommendations for IPG253Show all sections
Sections for IPG253
Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women.
Evidence-based recommendations on raloxifene and teriparatide for preventing osteoporotic fragility fractures in postmenopausal women who have osteoporosis.
(recommendation 1.3.5) recommends that all patients with all early oral squamous cell cancer SCC and N0 neck should be offered sentinel...
neoadjuvant endocrine therapy safe in premenopausal women with early breast cancer? Any explanatory notes(if applicable) To find out why...